Skip to main content
OpenTrials
Completed

NCT Number: NCT01023685

To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients

This study will investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

ATP Clinical Research, Inc., Costa Mesa, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who have completed the core study with no significant safety concerns

Exclusion criteria

  • Diagnosis of other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression).
  • Diagnosis or presence of an active, uncontrolled seizure disorder and/or cerebrovascular disease.
  • Diagnosis or presence of an active autoimmune and/or with an acute or chronic inflammation.

Other protocol-defined inclusion/exclusion criteria may apply

Treatment and study plan

CAD106

Biological

Primary outcomes

  1. Safety/tolerability assessments at multiple time points including but not limited to screening, and through to the end of the study to week 66.

    Time frame: 66 weeks

Secondary outcomes

  1. Collect long-term safety information through SAE's collection for two years after completion of the extension study.

    Time frame: 2 years

  2. Immune response, cognitive and functional assessments at multiple time points including but not limited to baseline, and through to the end of the study to week 66.

    Time frame: 66 weeks

  3. Evaluate the antibody response after 4 additional injections in the Extension study, in patients initially treated with CAD106 in the Core study.

    Time frame: 66 weeks

Sponsors and collaborators

Lead sponsor

Novartis

Industry

Registry information

Official study title

An Open-label Extension to a 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in Patients With Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106.

Important dates

Study start
2009
Primary completion
2012
Study completion
2012
First posted
Dec 2, 2009
Registry last updated
Dec 17, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.